4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments

1. A compound of formula I,

wherein:

R1 and R2 are independently of one another (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 4 )-alkyl, N[(C 1 -C 4 )-alkyl] 2 , OH, CN, F, Cl, Br, O-phenyl, CF 3 , OCF 3 or OCH 3 , wherein the alkyl moiety is optionally substituted one or more times by F, Cl, Br or CN;

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2, 3, 4 or 5;

V is O, S, SO or SO 2 ;

W is a bond, (C 1 -C 7 )-alkylene, (C 2 -C 7 )-alkenylene or (C 2 -C 7 )-alkynylene, wherein the alkylene, alkenylene and alkynylene are optionally substituted one or more times by R3;

X is mono-, bi- or tricyclic (C 3 -C 12 )-cycloalkyl ring, which is optionally substituted one or more times by R4;

Y is a bond, (C 1 -C 4 )-alkylene, (C 2 -C 4 )-alkenylene or (C 2 -C 4 )-alkynylene, wherein the alkylene, alkenylene and alkynylene are optionally substituted one or more times by R3;

R3 is NH 2 , NH(C 1 -C 4 )-alkyl, N[(C 1 -C 4 )-alkyl] 2 , F, Cl, Br, CN, OH, O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl or (C 2 -C 6 )-alkynyl, wherein the alkyl, alkenyl and alkynyl moieties are optionally substituted one or more times by F, Cl, Br or CN; and

R4 is F, Cl, Br, CN, (C 1 -C 4 )-alkyl or O—(C 1 -C 4 )-alkyl, wherein the alkyl moiety is optionally substituted one or more times by F, Cl, Br or CN;

or a physiologically tolerated salt thereof.

2. The compound according to claim 1 , wherein:

V is O, S or SO;

or a physiologically tolerated salt thereof.

3. The compound according to claim 1 , wherein:

R1 and R2 are independently of one another (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, OH, CN, F, Cl, Br, O-phenyl, CF 3 , OCF 3 or OCH 3 ;

V is O or S;

W is a bond or (C 1 -C 7 )-alkylene;

Y is a bond or (C 1 -C 4 )-alkylene; and

R4 is F, Cl, Br, CN, (C 1 -C 4 )-alkyl or O—(C 1 -C 4 )-alkyl;

or a physiologically tolerated salt thereof.

4. The compound according to claim 1 , wherein:

R1 and R2 are independently of one another (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, OH, CN, F, Cl, Br, O-phenyl, CF 3 , OCF 3 or OCH 3 ;

n is 0;

m is 0;

V is O or S;

W is bond or (C 1 -C 7 )-alkylene;

X is mono- or bicyclic (C 3 -C 12 )-cycloalkyl ring; and

Y is bond or (C 1 -C 4 )-alkylene;

or a physiologically tolerated salt thereof.

5. A pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising the compound according to claim 2 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

7. A pharmaceutical composition comprising the compound according to claim 3 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

8. A pharmaceutical composition comprising the compound according to claim 4 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient.

9. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 , or a physiologically tolerated salt thereof.

10. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 2 , or a physiologically tolerated salt thereof.

11. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 3 , or a physiologically tolerated salt thereof.

12. A method for lowering blood glucose, treating diabetes, or increasing insulin release, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 4 , or a physiologically tolerated salt thereof.

13. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 1 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 1 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

14. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 2 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient which comprises mixing the compound according to claim 2 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

15. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 3 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 3 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.

16. A process for manufacturing a pharmaceutical composition comprising the compound according to claim 4 or a physiologically tolerated salt thereof, in combination with a pharmaceutically acceptable excipient, which comprises mixing the compound according to claim 4 or the physiologically tolerated salt thereof, with the pharmaceutically acceptable excipient, and converting this mixture into a form suitable for administration.